We specifically chose the combined p53KD and oncogenic K-Ras genetic background given that loss of p53 combined with K-Ras mutations in human NSCLC is associated with a more aggressive malignancy [18]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.